TGFB1 and lymphoma: Moreover, the promise of inducing TGFβ1 resistance specifically in T cells is further highlighted by preclinical studies using a severe combined immunodeficient SCID xenograft model of Epstein-Barr virus (EBV)-positive lymphoma, which have revealed that EBV-specific CTL derived from patients and engineered to express dominant negative TGFβRII also confer enhanced tumor protection as compared to TGFβ1-sensitive CTL [151].